Eltrombopag Olamine (SB-497115-GR, SB497115; trade names: Promacta; Revolade), the olamine salt of Eltrombopag which is a member of the biarylhydrazone compounds, is a nonpeptide agonist of the thrombopoietin receptor (TpoR) approved as a medication to treat thrombocytopenia and severe aplastic anemia.

Avatrombopag maleate (formerly AKR501, YM477, AS1670542; E5501; AKR-501, YM-477, AS-1670542; E-5501; Doptelet), the maleate salt of Avatrombopag, is an orally bioactive thrombopoietin (TPO) receptor agonist approved in 2008 to treat patients with chronic idiopathic thrombocytopenic purpura.

Eltrombopag (formerly SB-497115; SB 497115; SB497115; trade name PROMACTA), a member of the biarylhydrazone class, is a novel nonpeptide agonist of the thrombopoietin receptor (TpoR) approved for use in the treatment of chronic hepatitis C-associated thrombocytopenia and chronic immune (idiopathic) thrombocytopenia (ITP).

Lusutrombopag (formerly known as S888711; S-888711; trade name: Mulpleta) is a novel orally bioavailable, small molecule agonist of thrombopoietin (TPO) receptor.

Avatrombopag (formerly AKR-501, YM-477, AS-1670542; E-5501; trade name: Doptelet) is an orally-active small molecule thrombopoietin (TPO) receptor agonist that was used for the first time in 2008 to treat patients with chronic idiopathic thrombocytopenic purpura.

Resmetirom (formerly known as MGL-3196, MGL 3196) is a novel, highly potent and selective agonist of the thyroid hormone receptor β (THR-β) with EC50 value of 0.21 μM.